Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen) Uniunea Europeană - română - EMA (European Medicines Agency)

aripiprazole mylan pharma (previously aripiprazole pharmathen)

mylan pharmaceuticals limited - aripiprazol - schizophrenia; bipolar disorder - psiholeptice - aripiprazol mylan pharma este indicat pentru tratamentul schizofreniei la adulți și adolescenți cu vârsta de 15 ani și peste. aripiprazole mylan pharma este indicat pentru tratamentul episoadelor maniacale moderate spre severe în tulburarea bipolară i și pentru prevenirea unui nou episod maniacal la adulți care au prezentat predominant episoade maniacale și ale căror episoade maniacale au răspuns la tratamentul cu aripiprazol. aripiprazole mylan pharma este indicat pentru tratamentul până la 12 săptămâni al episoadelor maniacale moderate spre severe în tulburarea bipolară i la adolescenți cu vârsta de 13 ani și mai în vârstă.

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) Uniunea Europeană - română - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agenți antitrombotici - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). supradenivelare de segment st infarct miocardic acut, în asociere cu aas în tratați medical, eligibili pentru tratamentul trombolitic. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pentru informații suplimentare vă rugăm să consultați secțiunea 5.

Pirfenidone Viatris Uniunea Europeană - română - EMA (European Medicines Agency)

pirfenidone viatris

viatris limited - pirfenidonă - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresoare - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

Dapagliflozin Viatris Uniunea Europeană - română - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - medicamente utilizate în diabet - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 și 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

KETAMINA PANPHARMA 50 mg/ml România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ketamina panpharma 50 mg/ml

panpharma gmbh - germania - ketaminum - sol. inj. - 50mg/ml - anestezice generale alte anestezice generale

Clopidogrel Taw Pharma (previously Clopidogrel Mylan) Uniunea Europeană - română - EMA (European Medicines Agency)

clopidogrel taw pharma (previously clopidogrel mylan)

taw pharma (ireland) limited - clopidogrel clorhidrat - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenți antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

ABACAVIR/LAMIVUDINA MYLAN PHARMA 600 mg/300 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abacavir/lamivudina mylan pharma 600 mg/300 mg

mcdermott laboratories limited t/a - irlanda - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii

TWICOR 10 mg/10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

twicor 10 mg/10 mg

pharmadox healthcare ltd. - malta - combinatii (rosuvastatinum+ezetimibum) - compr. film. - 10mg/10mg - hipolipemiante, combinatii hipolipemiante, combinatii

TWICOR 20 mg/10 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

twicor 20 mg/10 mg

pharmadox healthcare ltd. - malta - combinatii (rosuvastatinum+ezetimibum) - compr. film. - 20mg/10mg - hipolipemiante, combinatii hipolipemiante, combinatii

ABACAVIR/LAMIVUDINA VIATRIS 600 mg/300 mg România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

abacavir/lamivudina viatris 600 mg/300 mg

mcdermott laboratories limited t/a - irlanda - abacavirum+lamivudinum - compr. film. - 600mg/300mg - antivirale cu actiune directa antivirale pentru tratamentul infectiei cu hiv, combinatii